Genetic inhibition of vascular endothelial growth factor receptor-1 significantly inhibits the migration and proliferation of leukemia cells and increases their sensitivity to chemotherapy

Xiu,Bing; Zhang,Wenjun; Huang,Binbin; Chen,Jingde; Lu,Huina; Fu,Jianfei; Xiong,Hong; Liang,Aibin

doi:10.3892/or.2013.2348

Genetic inhibition of vascular endothelial growth factor receptor-1 significantly inhibits the migration and proliferation of leukemia cells and increases their sensitivity to chemotherapy

Authors:
- Bing Xiu
- Wenjun Zhang
- Binbin Huang
- Jingde Chen
- Huina Lu
- Jianfei Fu
- Hong Xiong
- Aibin Liang
View Affiliations

Affiliations: Department of Hematology, Tongji Hospital of Tongji University, Putuo, Shanghai 200065, P.R. China, Department of Oncology, Oriental Hospital of Tongji University, Pudong, Shanghai 200120, P.R. China
Published online on: March 13, 2013 https://doi.org/10.3892/or.2013.2348
Pages: 2030-2038

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Little is known about the role of vascular endothelial growth factor (VEGF) receptor-1 (VEGFR-1) in acute leukemia. In this study, using real-time PCR and ELISA, we found that VEGF and VEGFR-1 are highly expressed in U937 leukemia cells and primary leukemia cells (M4/M5 subtypes), which are associated with an increased migration rate and extramedullary disease. In order to elucidate the role of VEGFR-1 in acute leukemia, we used a lentivirus-mediated shRNA expression system to specifically inhibit VEGFR-1 expression in the U937 cell line. In addition, a series of in vitro experiments were conducted, including cell proliferation and migration assays and drug treatments. Our results showed that shRNA reduced the proliferation and migration of U937 cells. RNA interference targeting VEGFR-1 in combination with bevacizumab did not exert synergistic antitumor effects. However, shRNA enhanced the sensitivity of the U937 cells to cytarabine by decreasing the IC50 of cytarabine, reducing the number of cells in the S phase and suppressing the expression of the survivin gene. Taken together, these results suggest that VEGFR-1 interference may serve as a novel antitumor therapeutic strategy for the treatment of leukemia.

View Figures

View References

1	Aref S, El Sherbiny M, Goda T, Fouda M, Al Askalany H and Abdalla D: Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come. Hematology. 10:131–134. 2005. View Article : Google Scholar : PubMed/NCBI
2	de Bont ES, Fidler V, Meeuwsen T, Scherpen F, Hahlen K and Kamps WA: Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res. 8:2856–2861. 2002.PubMed/NCBI
3	Liang AB, Li L, Xie XT, et al: Preliminary study of VEGF and its receptor expression on childhood acute lymphoblastic leukemia and its relativity to clinical manifestations. Zhonghua Xue Ye Xue Za Zhi. 26:489–492. 2005.(In Chinese).
4	Podar K and Anderson KC: The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 105:1383–1395. 2005. View Article : Google Scholar : PubMed/NCBI
5	Fragoso R, Pereira T, Wu Y, Zhu Z, Cabeçadas J and Dias S: VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood. 107:1608–1616. 2006. View Article : Google Scholar : PubMed/NCBI
6	Elbashir SM, Harborth J, Weber K and Tuschl T: Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods. 26:199–213. 2002. View Article : Google Scholar : PubMed/NCBI
7	Hannon GJ: RNA interference. Nature. 418:244–251. 2002. View Article : Google Scholar : PubMed/NCBI
8	McManus MT and Sharp PA: Gene silencing in mammals by small interfering RNAs. Nat Rev Genet. 3:737–747. 2002. View Article : Google Scholar : PubMed/NCBI
9	Shi Y: Mammalian RNAi for the masses. Trends Genet. 19:9–12. 2003. View Article : Google Scholar
10	Hannon GJ and Rossi JJ: Unlocking the potential of the human genome with RNA interference. Nature. 431:371–378. 2004. View Article : Google Scholar : PubMed/NCBI
11	Filleur S, Courtin A, Ait-Si-Ali S, et al: SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. 63:3919–3922. 2003.
12	Shen HL, Xu W, Wu ZY, Zhou LL, Qin RJ and Tang HR: Vector-based RNAi approach to isoform-specific downregulation of vascular endothelial growth factor (VEGF)165 expression in human leukemia cells. Leuk Res. 31:515–521. 2007. View Article : Google Scholar
13	Manjunath N, Wu H, Subramanya S and Shankar P: Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev. 61:732–745. 2009. View Article : Google Scholar : PubMed/NCBI
14	Bellamy WT, Richter L, Sirjani D, et al: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 97:1427–1434. 2001. View Article : Google Scholar
15	Mukherji SK: Bevacizumab (Avastin). AJNR Am J Neuroradiol. 31:235–236. 2010. View Article : Google Scholar
16	Karp JE, Gojo I, Pili R, et al: Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-β-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res. 10:3577–3585. 2004.PubMed/NCBI
17	Kim KJ, Li B, Winer J, et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:841–844. 1993. View Article : Google Scholar : PubMed/NCBI
18	Zahiragic L, Schliemann C, Bieker R, et al: Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia. 21:1310–1312. 2007. View Article : Google Scholar : PubMed/NCBI
19	Santos SC and Dias S: Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood. 103:3883–3889. 2004. View Article : Google Scholar : PubMed/NCBI